Erastin: Precision Ferroptosis Inducer for Cancer Biology Research

Executive Summary. Erastin is a small molecule that induces ferroptosis, a form of iron-dependent, caspase-independent cell death, by targeting RAS/BRAF-mutant tumor cells [APExBIO]. Mechanistically, Erastin inhibits the cystine/glutamate antiporter system Xc⁻ and modulates VDAC, leading to lethal reactive oxygen species (ROS) accumulation [Dong et al., 2023]. Erastin is insoluble in water but dissolves in DMSO ≥10.92 mg/mL with warming and is best stored at −20°C [APExBIO]. It is widely used in cancer biology and oxidative stress research, especially in studies of RAS-RAF-MEK-driven malignancies. Peer-reviewed benchmarks confirm its reliability for inducing ferroptosis in vitro and in vivo [Dong et al., 2023].

Biological Rationale

Ferroptosis is a regulated, non-apoptotic cell death mechanism characterized by iron dependency and oxidative lipid damage. Unlike apoptosis or necrosis, ferroptosis is defined by distinctive mitochondrial changes, including cristae loss and membrane thickening [Dong et al., 2023]. Tumor cells with RAS (KRAS/HRAS) or BRAF mutations exhibit increased sensitivity to ferroptosis inducers such as Erastin. These mutations rewire redox metabolism, creating vulnerabilities that are exploited by Erastin-mediated system Xc⁻ inhibition. Exploiting ferroptosis pathways in cancer is a promising avenue to overcome resistance to traditional therapies, as demonstrated in bladder cancer and other solid tumors [Dong et al., 2023]. For an in-depth workflow comparison, see "Erastin (SKU B1524): Scenario-Driven Solutions for Reproducibility", which addresses laboratory optimization challenges; this article extends those findings by focusing on mechanistic specificity and benchmark data.

Mechanism of Action of Erastin

Erastin binds and modulates the voltage-dependent anion channel (VDAC) on the mitochondrial membrane, promoting increased permeability and ROS generation. Simultaneously, it inhibits the cystine/glutamate antiporter system Xc⁻ (SLC7A11), blocking cystine uptake and depleting intracellular glutathione (GSH). Glutathione depletion impairs GPX4 activity, resulting in uncontrolled lipid peroxidation and cell death. This mechanism is distinct from apoptosis, as it does not activate caspases or DNA fragmentation pathways. In RAS/BRAF-mutant cells, Erastin-induced oxidative stress is exacerbated by altered metabolic fluxes, making these cells particularly susceptible to ferroptosis. The molecular formula is C₃₀H₃₁ClN₄O₄ with a molecular weight of 547.04 g/mol [APExBIO]. For a detailed mechanistic analysis, compare with "Erastin: A Precision Ferroptosis Inducer for Cancer and RAS-Mutant Tumor Cells", which this article updates with new peer-reviewed benchmarks.

Evidence & Benchmarks

• Erastin (APExBIO, SKU B1524) induces ferroptosis in human bladder cancer 5637 cells, with increased ROS and malondialdehyde (MDA) at 10 μM for 24 h (Dong et al., 2023, https://doi.org/10.1155/2023/2830306).
• RNA-seq and Western blot confirm downregulation of AMPK pathway proteins and inhibition of autophagy following Erastin treatment in siMCT4-transfected cells (Dong et al., 2023, https://doi.org/10.1155/2023/2830306).
• Erastin does not induce classic apoptotic features (e.g., caspase activation, DNA laddering) in RAS/BRAF-mutant tumor cells, confirming ferroptotic specificity (Dong et al., 2023, https://doi.org/10.1155/2023/2830306).
• Colony formation and xenograft assays establish reduced tumor cell proliferation after Erastin exposure (Dong et al., 2023, https://doi.org/10.1155/2023/2830306).
• Erastin is insoluble in water and ethanol but soluble in DMSO (≥10.92 mg/mL) with gentle warming; stability is optimal at −20°C, and solutions should be freshly prepared (APExBIO, https://www.apexbt.com/erastin.html).

Applications, Limits & Misconceptions

Erastin is widely used in research on ferroptosis, cancer biology, oxidative stress, and cell death signaling. It is particularly valuable for dissecting the RAS-RAF-MEK pathway’s relationship to redox homeostasis and for screening compounds that modulate ferroptosis. However, it is not suitable for studies requiring induction of apoptosis or necrosis, nor does it affect cells lacking system Xc⁻ or VDAC expression. For translational workflows and troubleshooting, refer to "Erastin: A Ferroptosis Inducer Transforming Cancer Biology", which this article augments by clarifying selectivity and solubility parameters.

Common Pitfalls or Misconceptions

• Erastin is not a universal cytotoxin; its effects are selective for cells expressing system Xc⁻ and/or RAS/BRAF mutations.
• It does not induce apoptosis or necrosis; absence of caspase activation is a mechanistic hallmark.
• Erastin is unstable in solution for long-term storage; fresh preparation is required for each experiment.
• Water or ethanol cannot be used as solvents due to insolubility; only DMSO is validated for >10.92 mg/mL stock solutions.
• Ferroptosis induction by Erastin is iron-dependent and can be blocked by iron chelators or antioxidants.

Workflow Integration & Parameters

For reproducible results, Erastin should be stored as a solid at −20°C and dissolved in DMSO immediately before use. In vitro assays typically use concentrations of 10 μM for 24 h in engineered human tumor cells or HT-1080 fibrosarcoma lines. DMSO stocks (≥10.92 mg/mL) should be gently warmed to ensure complete solubilization. Controls should include vehicle (DMSO), iron chelators, and known apoptotic inducers to discriminate death modality. Downstream assays include measurement of ROS, lipid peroxidation, and cell viability, as established in peer-reviewed benchmarks [Dong et al., 2023]. For scenario-driven troubleshooting and assay optimization, consult "Erastin (SKU B1524): Scenario-Driven Solutions", which this article complements by providing a mechanistic context.

Conclusion & Outlook

Erastin, as provided by APExBIO (SKU B1524), is a robust and selective ferroptosis inducer for cancer biology and oxidative stress research. Its specificity for RAS/BRAF-mutant tumor cells and non-apoptotic mechanism distinguishes it from other cell death inducers. Stringent solubility and storage parameters are required for reproducibility. Ongoing research continues to expand its translational potential for cancer therapy targeting ferroptosis. For ordering or technical details, visit the Erastin product page.